Basiliximab er udviklet til at binde sig til antigenet CD25, som findes på overfladen af T- lymfocytter (en type hvide blodlegemer, der er involveret i afstødningen af organtransplantater).
Basiliximab has been designed to target an antigen called CD25, which is present on the surface of T-lymphocytes (a type of white blood cell that is involved in the rejection of organ transplants).